Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections

Current Opinion in Investigational Drugs

Volumn 5, Issue 8, 2004, Pages 838-850

  Beaulieu, Pierre L ^a   Tsantrizos, Youla S ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Allosteric inhibitors; HCV; HCV NS5B polymerase; Hepatitis C virus; Non nucleoside inhibitors; Nucleoside inhibitors; RNA dependent RNA polymerase

Indexed keywords

ANTIVIRUS AGENT; ENZYME INHIBITOR; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; NUCLEOSIDE; VIRUS PROTEIN;

ANIMAL; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; METABOLISM; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEOSIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 11144231108     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244(4902):359-362.
2. Wasley A, Alter MJ: Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis (2000) 20(1):1-16.
3. Berenguer M, Wright TL: Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies. Proc Assoc Am Physicians (1998) 110(2):98-112.
4. Forns X, Bukh J, Purcell RH: The challenge of developing a vaccine against hepatitis C virus. J Hepatol (2002) 37(5):684-695.
5. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C. Hepatology (2002) 36(5 Suppl 1):S121-S127.
6. Chandler G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA: Treatment of chronic hepatitis C: A systematic review. Hepatology (2002) 36(5B):S135-S144.
7. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S et al: Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. Arch Virol (1998) 143(12):2493-2503.
8. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K: Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA (1991) 88(13):5547-5551.
9. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM: Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 67(3):1385-1395.
10. Behrens SE, Tomei L, De Francesco R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 15(1):12-22.
11. Walker MP, Yao N, Hong Z: Promising candidates for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2003) 12(8):1269-1280.
12. Tan S-L, Pause A, Shi Y, Sonenberg N: Hepatitis C therapeutics: Current status and emerging strategies. Nat Rev Drug Discov (2003) 1(11):867-881.
13. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G: Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res (2003) 58(1):1-16.
14. Beaulieu PL, Llinàs-Brunet M: Therapies for hepatitis C infection. Curr Med Chem-Anti-Infective Agents (2002) 1:163-176.
15. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM: Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol (2000) 74(4):2046-2051.
16. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285(5424):110-113.
17. Bartenschlager R, Kaul A, Sparacio S: Replication of the hepatitis C virus in cell culture. Antiviral Res (2003) 60(2):91-102.
18. Landford RE, Bigger C, Bassett S, Klimpel G: The chimpanzee model of hepatitis C virus infection. ILAR J (2001) 42(2):117-126.
19. Grakoui A, Hanson HL, Rice CM: Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology (2001) 33(3):489-495.
20. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JRT, Tyrrell DLJ, Kneteman NM: Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 7(8):927-933.
21. Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Calleja JL, Forns X, Croenlein J, Nehmiz G, Steinmann G: First report on the antiviral efficacy of BILN 2061, a novel serine protease inhibitor, in patients with chronic hepatitis C, genotype 1. Hepatology (2002) 36(4 Pt 2):379A.
22. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM et al: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 426(6963):186-189.
23. Piccininni S, Varaklioti A, Nardelli M, Dave B, Raney KD, McCarthy JEG: Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. J Biol Chem (2002) 277(47):45670-45679.
24. Ishido S, Fujita T, Hotta H: Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. Biochem Biophys Res Commun (1998) 244(1):35-40.
25. Schmidt-Mende J, Bieck E, Hugle T, Penin F, Rice CM, Blum HE, Moradpour D: Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2001) 276(47): 44052-44063.
26. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Design (1999) 7(11):1417-1426.
27. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC: Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol (1999) 6(10):937-943.
28. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA (1999) 96(23):13034-13039.
29. Bressanelli S, Tomei L, Rey FA, De Francesco R: Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol (2002) 76(7):3482-3492.
30. O'Farrell D, Trowbridge R, Rowlands D, Jäger J: Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): Structural evidence for nucleotide import and de-novo initiation. J Mol Biol (2003) 326(4):1025-1035.
31. Ollis DL, Brick P, Hamlin R, Xuong NG, Steitz TA: Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP. Nature (1985) 313(6005):762-766.
32. Ranjith-Kumar CT, Gutshall L, Sarisky RT, Kao CC: Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis. J Mol Biol (2003) 330(4):675-685.
33. Hansen JL, Long AM, Schultz SC: Structure of the RNA-dependent RNA polymerase of poliovirus. Structure (1997) 5(8):1109-1122.
34. Miller RH, Purcell RH: Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci USA (1990) 87(6):2057- 2061.
35. Bougie I, Charpentier S, Bisaillon M: Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. J Biol Chem (2003) 278(6):3868-3875.
36. Shim JH, Larson G, Wu JZ, Hong Z: Selection of 3′-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J Virol (2002) 76(14):7030-7039.
37. Ranjith-Kumar CT, Kim Y-C, Gutshall L, Silverman C, Khandekar S, Sarisky RT, Kao CC: Mechanism of de novo initiation by the hepatitis C virus RNA-dependent RNA polymerase: Role of divalent metals. J Virol (2002) 76(24):12513-12525.
38. Zhong W, An H, Barawkar D, Hong Z: Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C virus. Antimicrob Agents Chemother (2003) 47(8):2674-2681.
39. Zhong W, Ferrari E, Lesburg CA, Maag D, Ghosh SKB, Cameron CE, Lau JYN, Hong Z: Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J Virol (2000) 74(19):9134-9143.
40. Hong Z, Cameron CE, Walker MP, Castro C, Yao N, Lau JYN, Zhong W: A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology (2001) 285(1):6-11.
41. McKercher G, Beaulieu PL, Lamarre D, LaPlante S, Lefebvre S, Pellerin C, Thauvette L, Kukolj G: Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucleic Acid Res (2004) 32(2):422-431.
42. Crotty S, Cameron CE, Andino R: RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci USA (2001) 98(12):6895-6900.
43. Maag D, Castro C, Hong Z, Cameron CE: Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem (2001) 276(49):46094-46098.
44. Lin C-C, Yeh L-T, Vitarella D, Hong Z: Viramidine, a prodrug of ribavirin, shown better liver-targeting properties and safety profiles than ribavirin in animals. Antiviral Chem Chemother (2003) 14(3):145-152.
45. Wu JZ, Hong Z: Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr Drug Targets Infect Disord (2003) 3(3):207-219.
46. Matsuda A, Takenuki K, Sasaki T, Ueda T: Nucleoside and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: Synthesis of (2′ S)-2′-deoxy-2′-C- methylcytidine, an antileukemic nucleoside. J Med Chem (1991) 34(1):234-239.
47. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA et al: Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem (2003) 278(14):11979-11984.
48. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R et al: Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 278(49):49164-49170.
49. Marquez VE, Ben-Kasus T, Barchi JJ Jr, Green KM, Nicklaus MC, Agbaria R: Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. J Am Chem Soc (2004) 126(2):543-549.
50. Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, Tomei L, Koch U, Neuner P: Discovery of α,γ-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. J Med Chem (2004) 47(1):14-17.
51. Beaulieu PL, Bös M, Bousquet Y, Fazal G, Gauthier J, Gillard J, Goulet S, LaPlante S, Poupart M-A, Lefebvre S, McKercher G et al: Nonnucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives. Bioorg Med Chem Lett (2004) 14(1):119-124.
52. Beaulieu PL, Bös M, Bousquet Y, DeRoy P, Fazal G, Gauthier J, Gillard l J, Goulet S, McKercher G, Poupart M-A, Valois S, Kukolj G: Nonnucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg Med Chem Lett (2004) 14(4):967-971.
53. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Genneri N, Bisbocci M, Incitti I, Orsatti L et al: Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol (2003) 77(24):13225-13231.
54. McHutchison JG, Patel K: Future therapy of hepatitis C. Hepatology (2002) 36(Suppl 1):S245-S252.
55. Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL et al: Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2002) 277(41):38322-38327.
56. Gu B, Johnston VK, Gutshall LL, Nguyen TT, Gontarek RR, Darcy MG, Tedesco R, Dhanak D, Duffy KJ, Kao CC, Sarisky RT: Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem (2003) 278(19):16602-16607.
57. Nguyen TT, Gates AT, Gutshall LL, Johnston VK, Gu B, Duffy KJ, Sarisky RT: Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother (2003) 47(11):3525-3530.
58. Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, Cellucci A, Forte E, Incitti I, Orsatti L, Koch U et al: Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol (2004) 78(2):938-946.
59. Chan L, Reddy TJ, Proulx M, Das SK, Pereira O, Wang W, Siddiqui A, Yannopoulos CG, Poisson C, Turcotte N, Drouin A et al: Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. J Med Chem (2003) 46(8):1283-1285.
60. Reddy TJ, Chan L, Turcotte N, Proulx M, Pereira OZ, Das SK, Siddiqui A, Wang W, Poisson C, Yannopoulos CG, Bilimoria D et al: Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase. Bioorg Med Chem Lett (2003) 13(19):3341-3344.
61. Chan L, Pereira O, Reddy TJ, Das SK, Poisson C, Courchesne M, Proulx M, Siddiqui A, Yannopoulos CG, Nguyen-Ba N, Roy C et al: Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: Tertiary amides. Bioorg Med Chem Lett (2004) 14(3):797-800.
62. Wang M, Ng KK-S, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, Nguyen-Ba N, Alaoui-Ismaili MH, Bethell RC, James MNG: Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem (2003) 278(11):9489-9495.
63. Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, Wriggers H, Ekker A, Wang L, Thomson JA, Dragovich PS, Fuhrman SA: Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol (2003) 77(13):7575-7581.
64. BRISTOL-MYERS SQUIBB CO (Romine JL, Martin SW, Snyder LB, Serrano-Wu M, Deshpande M, Whitehouse D, Lemm J, O'Boyle D, Gao M, Colonno R): Novel 5-(4-acylaminophenyl)-2-imino-thiazolidin-4-one derivatives and their use for the treatment of HCV infection. WO-2004014852 (2004).
65. BRISTOL-MYERS SQUIBB CO (Colonno R, Lemm J, O'Boyle D, Gao M, Romine JL, Martin SW, Snyder LB, Serrano-Wu M, Deshpande M, Whitehouse D): Combinations comprising an inhibitor of HCV NS5A protein function and another anti-HCV agent for treating HCV infection. WO-2004014313 (2004).
66. IDENIX CAYMAN LTD/UNIVERSITA DEGLI STUDI DI CAGLIARI (Sommadossi J-P, La Colla P): Novel 2′-C-methyl-β-D- ribofuranosylcytidine-3′-O-L-valine ester useful for treating flavivirus and pestivirus infections. WO-2004002422 (2004).
67. ISIS PHARMACEUTICALS INC/MERCK & CO INC (Bhat B, Bhat N, Dande P, Eldrup AB, Olsen DB, Maccoss M): Carbocyclic nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. WO-03105770 (2003).
68. ISIS PHARMACEUTICALS INC/MERCK & CO INC (Bhat B, Carroll SS, Eldrup AB, Maccoss M, Olsen DB, Prakash TP): Novel nucleoside derivatives as inhibitors of RNA-dependent RNA polymerase useful for treating viral infections. WO-2004007512 (2004).
69. ISIS PHARMACEUTICALS INC/MERCK & CO INC (Carroll SS, Olsen DB, Durette PL, Bhat B, Dande P, Eldrup AB): Nucleoside derivative viral polymerase inhibitors useful for the treatment of RNA-dependent RNA virus infections. WO-2004000858 (2003).
70. IDENIX (CAYMAN) LTD/CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/UNIVERSITA DEGLI STUDI DI CAGLIARI (Sommadossi J-P, La Colla P, Storer R, Gosselin G): Novel nucleoside prodrugs useful for the treatment of a host infected with a Flaviviridae virus, especially hepatitis C. WO-2004003000 (2004).
71. ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (Gardelli C, Giuliano C, Harper S, Koch U, Narjes F, Ontoria JM, Poma M, Ponzi S, Stansfield I, Summa V): Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors. WO-00206246 (2002).
72. VIROPHARMA INC (Bailey TR, Young DC): Compounds useful for treating or preventing flaviviral infections. WO-00010573 (2000).
73. VIROPHARMA INC (Bailey TR, Young DC): Methods for inhibiting Flaviviridae viruses using barbituric acid derivatives. WO-00013708 (2000).
74. VIROPHARMA INC (Young DC, Bailey TR): Methods for treating or preventing viral infections and associated diseases using 2-methylidenylbenzothiophenes. WO-00018231 (2000).
75. TULARIK INC (Jaen JC, Piper DE, Powers JP, Walker NPC, Li Y): NS5B HCV polymerase inhibitors. WO-00177091 (2001).
76. Yao N, An H, Appleby T, Nilar S, Ding Y, Hong Z: Inhibitors for de novo-RNA polymerases and methods of identifying targets for same. US-20030187000 (2003).
77. JAPAN TOBACCO INC (Hashimoto H, Mizutani K, Yoshida A): Novel fused-ring compounds useful for treating hepatitis C infection. WO-00147883 (2001).
78. BOEHRINGER INGELHEIM CANADA LTD (Beaulieu PL, Fazal G, Gillard J, Kukolj G, Austel V): Viral polymerase inhibitors. US-06448281 (2002).
79. BOEHRINGER INGELHEIM CANADA LTD (Beaulieu PL, Fazal G, Gillard J, Kukolj G, Austel V): Viral polymerase inhibitors. US-06479508 (2002).
80. BOEHRINGER INGELHEIM CANADA LTD (Beaulieu PL, Fazal G, Kukolj G, Jolicoeur E, Gillard J, Poupart M-A, Rancourt J): Novel bicyclic compounds which inhibit HCV polymerase. WO-03010140 (2003).
81. BOEHRINGER INGELHEIM CANADA LTD (Beaulieu PL, Fazal G, Goulet S, Kukolj G, Poirier M, Tsantrizos YS, Jolicoeur E, Gillard J, Poupart M-A, Rancourt J): Novel bicyclic compounds which inhibit HCV polymerase. WO-03010141 (2003).
82. BRISTOL-MYERS SQUIBB CO (Priestley ES, Decicco CP, Hudyma TW, Zheng X): Compounds useful for treating hepatitis C virus. WO-03026587 (2003).
83. NEOGENESIS PHARMACEUTICALS INC (Shipps GW Jr, Rosner KE, Popovici-Muller J, Deng Y, Wang T, Curran PJ): Novel pyrazolo[1,5 a]pyrimidine compounds useful as inhibitors of hepatitis C virus replication. WO-03101993 (2003).
84. BOEHRINGER INGELHEIM CANADA LTD (Beaulieu PL, Fazal G, Goulet S, Kukolj G, Poirier M, Tsantrizos YS): Novel azaheterocyclic amides or thioamide viral replication inhibitors. WO-03007945 (2003).
85. SMITHKLINE BEECHAM CORP (Dhanak D, Kaura AC, Shaw A): Novel quinolinone inhibitors of hepatitis C virus. WO-00185172 (2001).
86. SMITHKLINE BEECHAM CORP (Chai D, Darcy MG, Dhanak D, Duffy KJ, Erickson GA, Fitch DM, Gates AT, Johnston VK, Sarisky RT, Sharp MJ, Shaw AN et al): Novel antiviral 1,2,4-benzothiadiazine 1,1-dioxide derivatives. WO-02098424 (2002).
87. SMITHKLINE BEECHAM CORP (Darcy MG, Dhanak D, Duffy KJ, Fitch DM, Sarisky RT, Shaw AN, Tedesco R, Zimmerman MN): Novel nitrogen heterocycle compounds useful for the treatment of RNA virus infection, hepatitis C virus infection, hepatocellular carcinoma and liver fibrosis. WO-03059356 (2003).
88. SMITHKLINE BEECHAM CORP (Dhanak D, Duffy KJ, Sarisky RT, Shaw AN, Tedesco R): Novel anti-infectives. WO-03037262 (2003).
89. SMITHKLINE BEECHAM CORP (Duffy KJ, Evans KA, Fitch DM, Gates AT, Johnston VK, Sarisky RT): Novel 4-hydroxy-3-(1,1-dioxo-1,4-dihydrobenzo[1,2,4]thiadiazin-3-yl)-1, 5-dihydropyrrol-2-one derivatives useful for treating hepatitis C virus infection. WO-03099801 (2003).
90. SHIRE BIOCHEM INC (Chan CKL, Bidard J, Das SK, Pereira OZ, Shuttleworth S, Siddiqui MA, Wang W): Novel biaryl compounds useful for the treatment of flavivirus infections. WO-02100846 (2002).
91. SHIRE BIOCHEM INC (Chan CKL, Bidard J, Das SK, Nguyen BN, Pereira OZ, Reddy TJ, Siddiqui MA, Wang W, Yannopoulos C): Novel substituted thiophene compounds useful for the treatment of flavirus infections. WO-02100851 (2002).
92. SHIRE BIOCHEM INC (Kong LCC, Siddiqui MA): Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections. EP-01321463 (2003).
93. AGOURON PHARMACEUTICALS INC (Love RA, Yu X, Diehl W, Hickey MJ, Parge HE, Gao J, Fuhrman S): Hepatitis C virus (HCV) NS5B RNA polymerase and mutants thereof. EP-01256628 (2002).
94. PFIZER INC (Gonzalez J, Borchardt AJ, Dragovich PS, Jewell TM, Linton MA, Zhou R, Li H, Tatlock JH, Abreo MA, Prins TJ): Use of pyranone derivatives as inhibitors of hepatitis C virus RNA-dependent RNA polymerase. WO-03095441 (2003).
95. PFIZER INC (Borchardt AJ, Goble MP): Novel pyranone and pyrandiones useful as HCV polymerase inhibitors for treating hepatitis C virus infection. WO-03082848 (2003).
96. WYETH/VIROPHARMA INC (Gopalsamy A, Collette MS, Ellingboe JW, Laporte MG, Mansour TS, Burns CJ, Park K, Condon SM): The use of pyranoindole derivatives as hepatitis C polymerase inhibitors. WO-03099275 (2003).
97. WYETH/VIROPHARMA INC (Gopalsamy A, Ellingboe JW, Mansour TS): Novel (R)-enantiomers of pyranoindole compounds useful for treating hepatitis C viral infection. WO-03099824 (2003).
98. B&C BIOPHARM (Kim J-W, Lee S-W, Lee G-H, Han J-J, Park S-J, Park E-Y, Shin J-C): Novel 6-(4-substituted-anilino)pyrimidine derivatives useful for the treatment of HCV infection. WO-03084953 (2003).
99. FUJISAWA PHARMACEUTICAL CO LTD (Inoue T, Maki K, Hatakenaka K, Yamagishi Y): Novel compositions comprising fused benzene compounds useful as RNA-dependent RNA polymerase inhibitors for treating viral infections. WO-03082265 (2003).
100. DONG WHA P ARM IND CO LTD (Yoon S-J, Lee S-W, Lee J-S, Kim N-D, Lee G-H, Lee H-D, Kim J-W, Park S-J, Park H-J): 6-Methylnicotinamide derivatives as antiviral agents. WO-00178648 (2003).
101. DONG WHA PHARM IND CO LTD (Chung Y-H, Lee C-W, Yang W-Y, Lee H-D, Park W-J, Chang Y-Y, Lee J-S): Novel 2,4-difluorobenzamide derivatives as antiviral agents for treating HBV and HCV infections. WO-03002518 (2003).
102. DONG WHA PHARM IND CO LTD (Chung Y-H, Lee C-W, Yang W-Y, Lee H-D, Park W-J, Chang Y-Y, Lee J-S): Methoxy-1,3,5-triazine derivatives with activity against HBV and HCV polymerases. WO-02079187 (2002).
103. SMITHKLINE BEECHAM CORP (Dhanak D, Carr T): Novel heterocyclic compounds for the treatment of hepatitis C viral infection. WO-00185720 (2001).
104. GLAXO WELLCOME PLC (Bravi G, Goodland HS, Haigh D, Hartley CD, Lovegrove VLH, Shah P, Slater MJ): 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors. WO-03037894 (2003).
105. GLAXO WELLCOME PLC (Bravi G, Guidetti R, Haigh D, Hartley CD, Howes PD, Jackson DL, Lovegrove VLH, Shah P, Slater MJ, Wareing KJ): 4-(6-Membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors. WO-03037895 (2003).
106. GLAXO WELLCOME PLC (Slater MJ, Howes PD): Novel acyl bicyclic pyrrole derivative RNA-dependent RNA polymerase inhibitors useful for treating viral infections. WO-03097646 (2003).
107. GLAXO WELLCOME P LC (Bravi G, Howes PD, Lovegrove VLH, Shah P, Slater MJ): Acyl dihydro pyrrole derivatives as HCV inhibitors. WO-03037893 (2003).
108. GLAXO WELLCOME PLC (Burton G, Goodland HS, Haigh D, Kiesow TJ, Ku TW, Slater MJ): Novel 4-cyanopyrrolidine-2-carboxylic acid derivatives and their use as NS5B polymerase inhibitors for the treatment of viral infections, especially HCV infection. WO-2004009543 (2004).
109. PHARMACIA & UPJOHN CO (Battistini C, Casuscelli F, Kelly RC, Maggiora LL, Mitchell MA, Piutti C, Reding MT): Novel substituted diphenylamine derivatives useful for the treatment of HCV infection. WO-2004002940 (2004).
110. PHARMACIA & UPJOHN CO (Finzel BC, Funk LA, Kelly RC, Reding MT, Wicnienski NA): Novel substituted 2-aminobenzamide derivatives as inhibitors of viral RNA-dependent RNA polymerase useful for treating viral infections. WO-2004002944 (2004).
111. PHARMACIA & UPJOHN CO (Gao H, Greene ML, Gross RJ, Nugent RA, Pfefferkorn J): Novel amine substituted acrylic acid compounds useful for the treatment of viral infection, hepatitis and hepatitis C virus infection. WO-2004002977 (2004).
112. RIGEL PHARMACEUTICALS INC (Singh R, Goff D, Lu H, Issankani SD, Sun T): Novel hydrated p-toluenesulfonate salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2,4-dione. WO-03040112 (2003).
113. RIGEL PHARMACEUTICALS INC (Singh R, Goff D, Partridge J): Novel pyridyl-substituted heterocycles, useful for treating or preventing hepatitis C virus infection. WO-2004018463 (2004).